AC Immune (NASDAQ:ACIU) Earns Buy Rating from HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $16.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 393.83% from the company’s current price.

Separately, StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.24 on Wednesday. The firm has a 50 day simple moving average of $3.27 and a 200 day simple moving average of $3.45. The company has a market cap of $320.57 million, a price-to-earnings ratio of -4.50 and a beta of 1.28. AC Immune has a one year low of $2.25 and a one year high of $5.14.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million. As a group, analysts expect that AC Immune will post -0.89 EPS for the current year.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new stake in shares of AC Immune during the 1st quarter worth approximately $30,000. BNP Paribas Financial Markets grew its holdings in AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares during the period. Silverberg Bernstein Capital Management LLC bought a new position in shares of AC Immune during the 2nd quarter worth about $40,000. Vanguard Capital Wealth Advisors acquired a new stake in shares of AC Immune in the 2nd quarter valued at about $56,000. Finally, China Universal Asset Management Co. Ltd. increased its position in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.